Online citations, reference lists, and bibliographies.
← Back to Search

Treatment With Indinavir, Zidovudine, And Lamivudine In Adults With Human Immunodeficiency Virus Infection And Prior Antiretroviral Therapy.

R. Gulick, J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, E. Emini, J. Chodakewitz
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication. METHODS In this double-blind study, 97 HIV-infected patients who had received zidovudine treatment for at least 6 months and had 50 to 400 CD4 cells per cubic millimeter and at least 20,000 copies of HIV RNA per milliliter were randomly assigned to one of three treatments for up to 52 weeks: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours combined with 150 mg of lamivudine twice daily; or all three drugs. The patients were followed to monitor the occurrence of adverse events and changes in viral load and CD4 cell counts. RESULTS The decrease in HIV RNA over the first 24 weeks was greater in the three-drug group than in the other groups (P<0.001 for each comparison). RNA levels decreased to less than 500 copies per milliliter at week 24 in 28 of 31 patients in the three-drug group (90 percent), 12 of 28 patients in the indinavir group (43 percent), and none of 30 patients in the zidovudine-lamivudine group. The increase in CD4 cell counts over the first 24 weeks was greater in the two groups receiving indinavir than in the zidovudine-lamivudine group (P< or =0.01 for each comparison). The changes in the viral load and the CD4 cell count persisted for up to 52 weeks. All the regimens were generally well tolerated. CONCLUSIONS In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.
This paper references
10.1038/214470a0
Lymphocyte Survival in Men treated with X-rays for Ankylosing Spondylitis
K. Buckton (1967)
10.1126/SCIENCE.2183354
Rational design of peptide-based HIV proteinase inhibitors.
N. Roberts (1990)
Analyzing laboratory marker changes in AIDS clinical trials.
J. Dawson (1991)
10.1038/360264A0
Lifespan of human lymphocyte subsets defined by CD45 isoforms
C. Michie (1992)
10.1128/AAC.37.6.1390
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
Q. Gao (1993)
10.1128/AAC.37.4.875
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
R. Schinazi (1993)
10.1073/PNAS.90.12.5653
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
M. Tisdale (1993)
10.1073/PNAS.91.9.4096
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
J. Vacca (1994)
10.1177/009286159402800308
Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures
J. Dawson (1994)
10.1038/374569A0
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
J. Condra (1995)
10.1073/PNAS.92.7.2484
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
D. Kempf (1995)
10.1056/NEJM199512073332204
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
M. Markowitz (1995)
10.1093/INFDIS/171.6.1411
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
R. Schuurman (1995)
10.1056/NEJM199512213332502
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
J. Eron (1995)
10.2210/PDB1HPV/PDB
Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme
E. E. Kim (1995)
10.1056/NEJM199512073332303
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
S. Danner (1995)
Treatment with lamivudine , zidovudine , or both in HIV - positive patients with 200 to 500 CD 4 cells per cubic millimeter
JJ Eron (1995)
Antiretroviral activity of the oral protease inhibitor, MK-639, in p24 antigenemic, HIV-1 infected patients with Ͻ500 CD4/mm 3
J Mellors (1995)
10.1056/NEJM199610103351502
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
D. Katzenstein (1996)
10.1097/00002030-199610090-00007
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
D. Kuritzkes (1996)
10.1056/NEJM199604183341602
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
A. Collier (1996)
10.1001/JAMA.1996.03540020027025
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
T. O'Brien (1996)
10.1056/NEJM199602153340703
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
W. O'brien (1996)
10.1016/S0140-6736(96)05387-1
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
J. Darbyshire (1996)
10.1093/INFDIS/174.4.704
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
R. Coombs (1996)
10.1126/science.272.5265.1167
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
J. Mellors (1996)
10.7326/0003-4819-125-3-199608010-00001
Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection
J. Bartlett (1996)
10.1056/NEJM199610103351501
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
S. Hammer (1996)
10.1038/nm0796-760
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
A. Molla (1996)
10.1093/INFDIS/174.4.696
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
S. Welles (1996)
10.1128/jvi.70.12.8270-8276.1996
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
J. Condra (1996)
A trial comparing nucleoside monotherapy with combination therapy in HIV - infected adults with CD 4 cell counts from 200 to 500 per cubic millimeter
DA Katzenstein (1996)
The relation of vi - rologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV - infected adults with 200 to 500 CD 4 cells per cubic millimeter
NA Roberts (1996)
Treatment of human immunodeficiency virus infection with saquinavir , zidovudine , and zalcita - bine
JD Dawson (1996)
Changes in plasma HIV - 1 RNA and CD 4 lymphocyte counts and the risk of progression to AIDS
SL Welles (1996)
Reductions in HIV - 1 disease progression for AZT / 3 TC relative to control treatments : a meta analysis
KE Buckton
Antiretroviral activity of the oral protease inhibitor , MK - 639 , in p 24 antigenemic , HIV - 1 infected patients with  500 CD 4 / mm 3
JH Condra



This paper is referenced by
10.1007/s13337-021-00691-6
Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors
M. Hamed (2021)
10.1016/B978-0-12-814515-9.00126-0
Antiviral Classification
Guangdi Li (2021)
10.3389/fimmu.2021.637910
Dual Antiretroviral Therapy—All Quiet Beneath the Surface?
B. V. van Welzen (2021)
10.3389/fviro.2021.671745
Understanding the Struggle Between Viruses and the Immune System: A Quintessential Grand Challenge
M. Clerici (2021)
10.1021/acs.jcim.0c01457
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening
Anjela Manandhar (2021)
10.4081/AAMR.2020.129
Retrospective trend analysis of HIV viral load suppression among antiretroviral therapy clients in Bauchi State, Nigeria
Z. G. Ibrahim (2021)
10.1016/j.nantod.2020.101031
Nanotechnology for virus treatment
Jiarong Zhou (2021)
10.1016/j.ijpharm.2021.120621
Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
Yenju Chu (2021)
10.3389/fimmu.2021.638573
The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection
Yuqing Li (2021)
10.1097/COH.0000000000000694
Exosomes in HIV infection
Jing Chen (2021)
10.3390/v13081451
Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s)
G. Khoury (2021)
10.1186/s12985-021-01548-6
STING and cGAS gene expressions were downregulated among HIV-1-infected persons after antiretroviral therapy
Lorena Leticia Peixoto de Lima (2021)
10.3390/microorganisms9030566
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo
Courtney L. Finch (2021)
10.1016/j.jconrel.2020.10.036
Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach.
Chaolong Qin (2020)
10.1101/2020.05.22.111237
Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets
B. Castle (2020)
10.2174/1381612826666200417154810
An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets.
Anjali Sharma (2020)
10.1080/17512433.2020.1782737
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
10.1007/s11095-020-02847-3
Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing
R. Fernández-García (2020)
10.1007/s11904-020-00486-2
Novel Antiretroviral Agents
M. Cambou (2020)
10.1002/ange.202008071
Regio‐ and Diastereoselective Rhodium‐Catalyzed Allylic Substitution with Unstabilized Benzyl Nucleophiles
Debasis Pal (2020)
10.1007/s15006-020-0640-3
30 Jahre ART: Vom Todesurteil zur chronischen Erkrankung
Julian Hafner (2020)
10.1038/s41589-020-0496-y
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
T. Xiao (2020)
10.3389/fphar.2020.569766
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
P. Guo (2020)
10.1007/s40259-020-00413-2
Anti-HIV-1 Antibodies: An Update
Wanwisa Promsote (2020)
10.15252/emmm.202013426
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Vanessa Monteil (2020)
10.4038/SLLR.V34I2.36
Bibliometric analysis of the most cited articles in urolithiasis
Komathy Murugathas (2020)
10.1002/adtp.201900135
Simultaneous Optimization of Drug Combination Dose‐Ratio Sequence with Innovative Design and Active Learning
Aiting Wang (2020)
10.1172/JCI141497
Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists.
J. Siliciano (2020)
10.1038/s41598-020-70950-x
Neurotoxicity of HIV-1 Tat is attributed to its penetrating property
Xiaoli Tang (2020)
10.15212/caet/2020/6/7
Virus – On the Edge of Art and Science, Human Beings, and Nature
T. Zhou (2020)
10.3390/ijms21134649
In Situ Detection of Endogenous HIV Activation by Dynamic Nuclear Polarization NMR and Flow Cytometry
Sarah A. Overall (2020)
10.1070/rcr4919
Modifications at the C(5) position of pyrimidine nucleosides
W. Kozak (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar